NO20040973L - Anvendelse av 4-pyridylmetylftalaziner for kreftbehandling - Google Patents

Anvendelse av 4-pyridylmetylftalaziner for kreftbehandling

Info

Publication number
NO20040973L
NO20040973L NO20040973A NO20040973A NO20040973L NO 20040973 L NO20040973 L NO 20040973L NO 20040973 A NO20040973 A NO 20040973A NO 20040973 A NO20040973 A NO 20040973A NO 20040973 L NO20040973 L NO 20040973L
Authority
NO
Norway
Prior art keywords
pyridylmethylphthalazines
cancer treatment
phthalazine
pyridylmethyl
treated
Prior art date
Application number
NO20040973A
Other languages
English (en)
Other versions
NO327358B1 (no
Inventor
Jeanette Marjorie Wood
Margaret Han Dugan
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of NO20040973L publication Critical patent/NO20040973L/no
Publication of NO327358B1 publication Critical patent/NO327358B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
NO20040973A 2001-09-12 2004-03-05 Anvendelse av en kombinasjon for behandling av proliferative sykdommer NO327358B1 (no)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US31869401P 2001-09-12 2001-09-12
US33102501P 2001-09-12 2001-09-12
US32204401P 2001-09-14 2001-09-14
US38816302P 2002-06-12 2002-06-12
PCT/EP2002/010194 WO2003022282A1 (en) 2001-09-12 2002-09-11 Use of 4-pyridylmethylphthalazines for cancer treatment

Publications (2)

Publication Number Publication Date
NO20040973L true NO20040973L (no) 2004-06-03
NO327358B1 NO327358B1 (no) 2009-06-15

Family

ID=27502161

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20040973A NO327358B1 (no) 2001-09-12 2004-03-05 Anvendelse av en kombinasjon for behandling av proliferative sykdommer

Country Status (22)

Country Link
US (2) US20040258770A1 (no)
EP (1) EP1427420B1 (no)
JP (1) JP2005502690A (no)
KR (1) KR20040029172A (no)
CN (1) CN1330308C (no)
AT (2) ATE329597T1 (no)
AU (2) AU2002342678B2 (no)
BR (1) BR0212446A (no)
CA (1) CA2457848A1 (no)
CO (1) CO5560545A2 (no)
CY (1) CY1105189T1 (no)
DE (2) DE60212415T2 (no)
DK (1) DK1427420T3 (no)
ES (2) ES2266590T3 (no)
HR (1) HRP20040241A2 (no)
IL (1) IL160382A0 (no)
NO (1) NO327358B1 (no)
NZ (1) NZ531484A (no)
PL (1) PL367349A1 (no)
PT (1) PT1427420E (no)
RS (1) RS16804A (no)
WO (1) WO2003022282A1 (no)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0223341D0 (en) * 2002-10-08 2002-11-13 Groningen Acad Ziekenhuis Organic compounds
JP2006514991A (ja) * 2002-12-27 2006-05-18 シエーリング アクチエンゲゼルシャフト 新規医薬組合せ
AU2003233586A1 (en) * 2003-05-20 2005-01-21 Aronex Pharmaceuticals, Inc. Combination chemotherapy comprising capecitabine and a liposomal platinum complex
AU2004273615B2 (en) * 2003-09-23 2009-01-15 Novartis Ag Combination of a VEGF receptor inhibitor with a chemotherapeutic agent
GB0610925D0 (en) * 2006-06-02 2006-07-12 Novartis Ag Use of vascular endothelial growth factor receptor inhibitors for the treatment of cancer
KR101037292B1 (ko) * 2010-09-03 2011-05-27 (주)슈추어 신발 장식구

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE267174T1 (de) * 1994-08-09 2004-06-15 Eisai Co Ltd Kondensierte pyridazinverbindungen
KR100489174B1 (ko) * 1996-03-05 2005-09-30 제네카-파마 소시에떼아노님 4-아닐리노퀴나졸린유도체
US6096904A (en) * 1996-12-03 2000-08-01 The Trustees Of The University Of Pennsylvania Synthetic techniques and intermediates for polyhydroxy, dienyl lactone derivatives
CO4950519A1 (es) * 1997-02-13 2000-09-01 Novartis Ag Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion

Also Published As

Publication number Publication date
CN1553803A (zh) 2004-12-08
DE60231068D1 (de) 2009-03-19
AU2006203428A1 (en) 2006-08-31
IL160382A0 (en) 2004-07-25
JP2005502690A (ja) 2005-01-27
PT1427420E (pt) 2006-10-31
NZ531484A (en) 2007-02-23
ATE329597T1 (de) 2006-07-15
PL367349A1 (en) 2005-02-21
NO327358B1 (no) 2009-06-15
CA2457848A1 (en) 2003-03-20
RS16804A (en) 2007-02-05
HRP20040241A2 (en) 2005-04-30
KR20040029172A (ko) 2004-04-03
DE60212415T2 (de) 2006-11-23
DK1427420T3 (da) 2006-10-02
DE60212415D1 (de) 2006-07-27
ES2320922T3 (es) 2009-05-29
EP1427420A1 (en) 2004-06-16
US20090196871A1 (en) 2009-08-06
BR0212446A (pt) 2004-08-17
CN1330308C (zh) 2007-08-08
US20040258770A1 (en) 2004-12-23
WO2003022282A1 (en) 2003-03-20
AU2002342678B2 (en) 2006-08-24
ES2266590T3 (es) 2007-03-01
CY1105189T1 (el) 2010-03-03
AU2006203428B2 (en) 2009-06-04
CO5560545A2 (es) 2005-09-30
ATE421880T1 (de) 2009-02-15
EP1427420B1 (en) 2006-06-14

Similar Documents

Publication Publication Date Title
DK1378240T3 (da) Farmaceutiske præparater omfattende arsentrioxid til behandling af multipelt myelom
MX2009006779A (es) Antagonistas especificos para terapia con adyuvantes y neo-adyuvantes y el tratamiento de tumores en etapa temprana.
NO20062885L (no) Terapeufiske anti-IGFR1-antistoffkombinasjoner
MX342777B (es) Inhibidores tnfa para usarse en el tratamiento de trastornos relacionados con tnfa.
EA201000016A1 (ru) Способы и композиции для лечения рака, опухолей и нарушений, связанных с опухолями
NO20091661L (no) Anvendelse av pegylert IL-10 for a behandle kreft
PL415000A1 (pl) Zastosowanie 40-O-(2-hydroksyetylo)-rapamycyny do wytwarzania leku do leczenia litych guzów ośrodkowego układu nerwowego
WO2002092854A3 (en) Genes expressed in breast cancer as prognostic and therapeutic targets
NO20071585L (no) Ny anvendelse av peptidforbindelser for behandling av benkreftsmerte, kjemoterapi- og nucleosidfremkalt smerte
EA200301104A1 (ru) Антиангиогенная комбинированная терапия для лечения онкологических заболеваний
IS7137A (is) Samsett meðferð til meðhöndlunar á krabbameini
HK1068261A1 (en) Combinations comprisinga selective cyclooxygenase-2 inhibitor
ATE478076T1 (de) Azaxanthonen zur behandlung von tumoren
DE60141194D1 (de) Behandlung des metastasierenden Karzinoms der Niere
NO20040973L (no) Anvendelse av 4-pyridylmetylftalaziner for kreftbehandling
HK1056692A1 (en) Proteins
BG108932A (en) Pharmaceutical composition comprising arsenite for the treatment of malignancy
MXPA04002407A (es) Uso de 4-piridilmeetil-ftalazinas para el tratamiento de cancer.
DE69912477D1 (de) Endokrintherapie für brustkrebs: kombinierte behandlung mit tamoxifen und alkyl-pcdfs
ECSP044991A (es) Uso de 4-piridilmetil-ftalazinas para el tratamiento de cancer
WO2005048956A3 (en) Estradiol-related compounds and methods of use as anti-tumor agents
TW200626150A (en) Use of Epothilones in the treatment of bone metastasis
EA200600987A1 (ru) Применение сирамезина в лечении злокачественных опухолей
UA49216A (uk) Засіб для лікування ускладнень після видалення злоякісних новоутворень шкіри
ZA200408071B (en) Combination therapy for the treatment of cancer.

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees